NAYA Biosciences Inc. - רווח תפעולי EBITDA NAYA

NAYA Biosciences is implementing the Flex-NK platform to activate immune cells against tumors. This EBITDA chart visualizes current cash flow, where the value of corresponds to the current metric. The asset's value is based on patents in the absence of market sales, while future success in antibody biosynthesis will provide the company with powerful scaling leverage.

NAYA Biosciences is scaling its developments in gene modification for oncology and reproductive medicine, building long-term scientific capital. This trend in absolute profit from core operations measures the daily liquidity inflow net of financial expenses, allowing investors to promptly identify any degradation in the business's operational efficiency prior to the publication of official quarterly reports.